These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 27506741)
1. The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges. Yang P; Huang T; Xu G Metabolism; 2016 Sep; 65(9):1342-9. PubMed ID: 27506741 [No Abstract] [Full Text] [Related]
2. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025 [TBL] [Abstract][Full Text] [Related]
3. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y; J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025 [TBL] [Abstract][Full Text] [Related]
4. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ; Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812 [TBL] [Abstract][Full Text] [Related]
5. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B; Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733 [TBL] [Abstract][Full Text] [Related]
6. Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease? Doggrell SA Expert Opin Pharmacother; 2021 Jul; 22(10):1253-1256. PubMed ID: 33764251 [No Abstract] [Full Text] [Related]
19. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469 [TBL] [Abstract][Full Text] [Related]
20. New pharmacological strategies for protecting kidney function in type 2 diabetes. Muskiet MHA; Wheeler DC; Heerspink HJL Lancet Diabetes Endocrinol; 2019 May; 7(5):397-412. PubMed ID: 30579729 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]